CURE Spring 2025

CURE spoke with experts about what life is like for patients in the survivorship care period.

CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.

The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.

Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.